641 related articles for article (PubMed ID: 34452286)
1. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.
Nettelbeck DM; Leber MF; Altomonte J; Angelova A; Beil J; Berchtold S; Delic M; Eberle J; Ehrhardt A; Engeland CE; Fechner H; Geletneky K; Goepfert K; Holm PS; Kochanek S; Kreppel F; Krutzke L; Kühnel F; Lang KS; Marchini A; Moehler M; Mühlebach MD; Naumann U; Nawroth R; Nüesch J; Rommelaere J; Lauer UM; Ungerechts G
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452286
[TBL] [Abstract][Full Text] [Related]
2. Virotherapy Research in Germany: From Engineering to Translation.
Ungerechts G; Engeland CE; Buchholz CJ; Eberle J; Fechner H; Geletneky K; Holm PS; Kreppel F; Kühnel F; Lang KS; Leber MF; Marchini A; Moehler M; Mühlebach MD; Rommelaere J; Springfeld C; Lauer UM; Nettelbeck DM
Hum Gene Ther; 2017 Oct; 28(10):800-819. PubMed ID: 28870120
[TBL] [Abstract][Full Text] [Related]
3. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.
Kontermann RE; Ungerechts G; Nettelbeck DM
MAbs; 2021; 13(1):1982447. PubMed ID: 34747345
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.
Li M; Zhang M; Ye Q; Liu Y; Qian W
Cancer Biol Med; 2023 Aug; 20(9):646-61. PubMed ID: 37615308
[TBL] [Abstract][Full Text] [Related]
5. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
6. Introduction to Oncolytic Virotherapy.
Engeland CE; Bell JC
Methods Mol Biol; 2020; 2058():1-6. PubMed ID: 31486028
[TBL] [Abstract][Full Text] [Related]
7. Development of oncolytic viruses for cancer therapy.
Abd-Aziz N; Poh CL
Transl Res; 2021 Nov; 237():98-123. PubMed ID: 33905949
[TBL] [Abstract][Full Text] [Related]
8. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
9. Engineering and combining oncolytic measles virus for cancer therapy.
Leber MF; Neault S; Jirovec E; Barkley R; Said A; Bell JC; Ungerechts G
Cytokine Growth Factor Rev; 2020 Dec; 56():39-48. PubMed ID: 32718830
[TBL] [Abstract][Full Text] [Related]
10. Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.
Hiss DC; Fielding BC
Expert Opin Biol Ther; 2012 Nov; 12(11):1427-47. PubMed ID: 22788715
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virotherapy.
Russell SJ; Peng KW; Bell JC
Nat Biotechnol; 2012 Jul; 30(7):658-70. PubMed ID: 22781695
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation in Oncolytic Measles Virotherapy.
Dietz L; Engeland CE
Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status.
Zhang Y; Liu Z
Curr Pharm Des; 2019; 25(40):4251-4263. PubMed ID: 31682207
[TBL] [Abstract][Full Text] [Related]
14. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
Sinkovics JG; Horvath JC
Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
[TBL] [Abstract][Full Text] [Related]
15. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Virotherapy by HSV.
Watanabe D; Goshima F
Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
18. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic viruses: what to expect from their use in cancer treatment.
Terrível M; Gromicho C; Matos AM
Microbiol Immunol; 2020 Jul; 64(7):477-492. PubMed ID: 31663631
[TBL] [Abstract][Full Text] [Related]
20. Advances in viral oncolytics for treatment of multiple myeloma - a focused review.
Sarwar A; Hashim L; Faisal MS; Haider MZ; Ahmed Z; Ahmed TF; Shahzad M; Ansar I; Ali S; Aslam MM; Anwer F
Expert Rev Hematol; 2021 Dec; 14(12):1071-1083. PubMed ID: 34428997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
